Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-08 10:05 am Purchase |
2023-12-29 | 13G | Akero Therapeutics, Inc. AKRO |
WELLINGTON MANAGEMENT CO LLP | 2,881,989 5.170% |
2,005,890 (+228.96%) |
Filing History |
| 2024-02-07 07:23 am Sale |
2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
ADAGE CAPITAL PARTNERS GP LLC | 275,000 0.490% |
-2,527,627 (-90.19%) |
Filing History |
| 2024-01-26 11:49 am Purchase |
2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
BLACKROCK INC BLK |
4,180,507 7.500% |
1,421,978 (+51.55%) |
Filing History |
| 2024-01-25 09:36 am Purchase |
2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
STATE STREET CORP STT |
5,122,895 9.200% |
2,621,926 (+104.84%) |
Filing History |
| 2023-09-12 4:30 pm Sale |
2023-09-08 | 13G | Akero Therapeutics, Inc. AKRO |
Skorpios Trust | 0 0.000% |
-3,271,829 (Position Closed) |
Filing History |
| 2023-04-10 4:59 pm Purchase |
2023-03-30 | 13G | Akero Therapeutics, Inc. AKRO |
ADAGE CAPITAL PARTNERS GP LLC | 2,802,627 5.970% |
2,802,627 (New Position) |
Filing History |
| 2023-02-14 4:31 pm Sale |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Atlas Venture Fund XI, L.P. | 467,529 1.000% |
-1,496,000 (-76.19%) |
Filing History |
| 2023-02-14 4:23 pm Purchase |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Redmile Group LLC | 2,632,912 5.600% |
1,030,627 (+64.32%) |
Filing History |
| 2023-02-14 4:02 pm Sale |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Point72 Asset Management, L.P. | 115,484 0.200% |
-1,644,764 (-93.44%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Baker Bros. Advisors LP | 2,368,378 5.100% |
2,368,378 (New Position) |
Filing History |
| 2023-02-14 2:58 pm Purchase |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Avidity Partners Management LP | 3,825,000 8.200% |
720,000 (+23.19%) |
Filing History |
| 2023-02-14 12:38 pm Purchase |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
PRICE T ROWE ASSOCIATES INC | 2,401,037 5.100% |
2,401,037 (New Position) |
Filing History |
| 2023-02-13 10:54 am Purchase |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
ALKEON CAPITAL MANAGEMENT LLC | 3,243,915 6.900% |
764,244 (+30.82%) |
Filing History |
| 2023-02-10 11:27 am Purchase |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
JANUS HENDERSON GROUP PLC JHG |
3,340,174 7.100% |
176,552 (+5.58%) |
Filing History |
| 2023-02-07 4:31 pm Sale |
2022-12-30 | 13G | Akero Therapeutics, Inc. AKRO |
GOLDMAN SACHS GROUP INC GS |
474,564 1.000% |
-1,301,628 (-73.28%) |
Filing History |
| 2023-02-06 2:43 pm Sale |
2022-12-30 | 13G | Akero Therapeutics, Inc. AKRO |
WELLINGTON MANAGEMENT CO LLP | 876,099 1.870% |
-1,000,712 (-53.32%) |
Filing History |
| 2023-02-03 2:06 pm Purchase |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
STATE STREET CORP STT |
2,500,969 5.350% |
2,500,969 (New Position) |
Filing History |
| 2023-02-03 12:09 pm Purchase |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
BLACKROCK INC BLK |
2,758,529 5.900% |
494,286 (+21.83%) |
Filing History |
| 2022-12-05 4:40 pm Sale |
2022-12-01 | 13G | Akero Therapeutics, Inc. AKRO |
Skorpios Trust | 3,271,829 7.000% |
-1,636,000 (-33.33%) |
Filing History |
| 2022-11-09 2:21 pm Purchase |
2021-10-31 | 13G | Akero Therapeutics, Inc. AKRO |
BLACKROCK INC BLK |
2,264,243 4.900% |
320,121 (+16.47%) |
Filing History |